Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 3/20 | 0.52 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.52 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.52 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.52 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.52 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.52 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.52 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.52 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.52 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.52 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.52 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.52 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.52 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.52 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.52 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104314 | 0.97 | GABRA1 (0.55) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| Lithium Ion SCHEMBL29536467 | 0.94 | GABRA1 (0.52) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL6692957 | 0.94 | GABRA1 (0.52) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| Methane SCHEMBL27577653 | 0.94 | GABRA1 (0.52) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL30791052 | 0.94 | GABRA1 (0.52) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| Lithium SCHEMBL30421854 | 0.94 | GABRA1 (0.52) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| Cyclohexane SCHEMBL27557640 | 0.90 | GABRA1 (0.48) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| Propane SCHEMBL27557470 | 0.90 | GABRA1 (0.48) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL14081995 | 0.87 | GABRA1 (0.52) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL28105462 | 0.87 | LMNA (0.46) | GABRA1LMNAGABRG2GABRB3GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162160-A1 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO | MILLENDO THERAPEUTICS, INC. | 2022-05-26 | — | — | US | claimed |
| US-20200255372-A1 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO | MILLENDO THERAPEUTICS INC (US) | 2020-08-13 | — | — | US | claimed |
| EP-3197435-A1 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL) METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO | Millendo Therapeutics, Inc. (US) | 2017-08-02 | — | — | EP | claimed |
| WO-2016049518-A1 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL) METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO | MILLENDO THERAPEUTICS, INC. (US) | 2016-03-31 | — | — | WO | claimed |
| US-20160090354-A1 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-03-31 | — | — | US | claimed |
| JP-2040348-A | — | — | None | — | — | JP | disclosed |
| CN-122010847-A | Synthesis method of 1- [3, 5-bis (1-methylethyl) [1,1' -biphenyl ] -4-yl ] -2-bromo-1H-benzimidazole | 安徽大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2025-04-10 | — | — | US | disclosed |
| US-12151998-B2 | Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-11-26 | — | — | US | disclosed |
| US-11981667-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2024-05-14 | — | — | US | disclosed |
| CN-111018718-B | Preparation method of halogen substituted alkylaniline | 青岛凯源祥化工有限公司 | 2023-02-07 | — | — | CN | disclosed |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2023-02-02 | — | — | US | disclosed |
| EP-0588608-A2 | Tricyclic compounds and pharmaceutical compositions containing them | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-03-23 | — | — | EP | disclosed |
| EP-0347380-B1 | PROCESS FOR THE PREPARATION OF 4-BROMOANILINE-HYDROBROMIDE | CIBA-GEIGY AG (CH) | 1993-02-10 | — | — | EP | disclosed |
| US-5055616-A | 9,9-bis(3-alkyl-4-amino-5-isopropylphenyl) fluorene; for use in gas separation membranes | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1991-10-08 | — | — | US | disclosed |
| US-5045093-A | Gas separating membranes from polyimide polymers and a process for using the same | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1991-09-03 | — | — | US | disclosed |
| US-4918230-A | BROMINATION OF ANILINE HYDROHALIDE; BY-PRODUCT INHIBITION | CIBA-GEIGY CORPORATION (US) | 1990-04-17 | — | — | US | disclosed |
| JP-H0240348-A | PREPARATION OF 4-BROMOANILINE HYDROBROMIDE | CIBA GEIGY AG | 1990-02-09 | — | — | JP | disclosed |
| EP-0347380-A1 | Process for the preparation of 4-Bromoaniline-hydrobromide | CIBA-GEIGY AG (CH) | 1989-12-20 | — | — | EP | disclosed |
| US-4289906-A | Chemical process for preparing methylene bis-anilines | ETHYL CORPORATION (US) | 1981-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090354-A1 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO | ATR, BAP1, ATRIP | GABRA1 1296/4885GABRG2 1706/4885GABRB3 1890/4885 |
| US-12151998-B2 | Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto | ATR, BAP1, ATRIP | GABRA1 1291/4885GABRG2 1701/4885GABRB3 1864/4885 |
| US-20220162160-A1 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO | ATR, BAP1, ATRIP | GABRA1 1296/4885GABRG2 1706/4885GABRB3 1890/4885 |
| US-20200255372-A1 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO | ATR, BAP1, ATRIP | GABRA1 1296/4885GABRG2 1706/4885GABRB3 1890/4885 |
| US-11981667-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, PYCARD | GABRA1 2480/4885GABRG2 2970/4885GABRB3 1960/4885 |
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | GABRA1 2534/4885GABRG2 2986/4885GABRB3 1851/4885 |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | GABRA1 2736/4885GABRG2 3122/4885GABRB3 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.